Business Context and Reporting Period
This Form 8-K was filed by Aerpio Pharmaceuticals, Inc. on March 18, 2019. The filing reports on a specific corporate event rather than a standard financial reporting period. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on clinical trial results rather than financial performance.
Material Changes
The primary material event reported is the announcement of results from the TIME-2b Study of the company's investigational drug, AKB-9778, for the treatment of diabetic retinopathy. A press release detailing these results is attached as Exhibit 99.1.
Guidance, Outlook, and Risks
Management commentary is limited to the issuance of the press release regarding the TIME-2b study results. The filing does not contain updated financial guidance, specific risk factors, or contingencies beyond the standard disclosure of the clinical trial announcement.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific efficacy and safety data from the TIME-2b study.
- Verify the clinical significance of the AKB-9778 results for diabetic retinopathy.
- Check for subsequent regulatory filings or investor presentations that may provide financial context or updated development timelines.